Clinical trial
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
NCT00047216 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00047216 |
|---|---|
| Title | Tipifarnib in Treating Patients With Recurrent Bladder Cancer |
| Official title | A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | tipifarnib |
| Start date | Nov 1, 2002 |
| Primary completion | Mar 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: